Enzo Biochem/GeneNews ink colorectal cancer test pact
This article was originally published in The Gray Sheet
Executive Summary
Enzo gains rights to market GeneNews' ColonSentry colorectal cancer test in New York and New Jersey under an agreement announced Nov. 18. The firm said it hopes to launch the test in the second half of 2010 after securing CLIA certification and third-party reimbursement. According to GeneNews, ColonSentry is the first blood test for colorectal cancer, and offers a non-invasive method of assessing cancer risk that may improve screening compliance rates and lead to earlier detection